Skip to Main Content
Yale School of Medicine
About YSM
Faculty
Staff
Students
Residents & Fellows
Patients
Researchers
Alumni
Yale School of Medicine
/
Neurosurgery
MENU
Make a Gift
Yale School of Medicine
MENU
Neurosurgery
Make a Gift
About Us
About the Chair
Collaborative Excellence
Faculty & Staff
A-Z Listing
Patient Care
Education & Training
Neurosurgery Residency Program
How to Apply
Current Residents
Resident Awards
Michael L.J.Apuzzo Award for Creativity and Innovation
William F. Collins, Jr. M.D. Neurosurgery Resident Research Symposium
Dr. Paul Kalanithi Award for Professional Excellence in Neurosurgery
James D. Prokop, MD Lecture in Neurosurgery
Dennis D. Spencer Award in Academic Achievement
Alumni
Fellowships
Yale Medical Student Clerkship
Medical Student Subinternship
Physician/Student Observership
International Student Elective Program
Cushing Society
Research
Research Expertise
Clinical Trials
Publications
Basic Science Research Labs
Clinical Research
Yale Program in Brain Tumor Research
News & Events
Events
Newsletter
Ways to Give
Named Lectureships
Donations
YSM Home
INFORMATION FOR
About YSM
Faculty
Staff
Students
Residents & Fellows
Patients
Researchers
Alumni
Home
Research
Research Expertise
Clinical Trials
Publications
Basic Science Research Labs
Clinical Research
Yale Program in Brain Tumor Research
Clinical Trials
Myeloid and Monocytic Leukemia
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Brain and Nervous System
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
Myeloid and Monocytic Leukemia
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis
Phase I
An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M0324, a Bispecific (MUC-1 x CD40) Antibody as Monotherapy, in Combination With Pembrolizumab, and in Combination With Chemotherapy, in Participants With Selected Advanced Solid Tumors
Show More
Back to Top
Your browser is antiquated and no longer supported on this website. Please update your browser or switch to Chrome, Firefox or Safari.
You can update your IE here:
https://support.microsoft.com/en-us/help/17621/internet-explorer-downloads
[8330,3053]
{"namedChunks":["modules-page-components-ComponentWrapper","features-clinical-trial-components-ClinicalTrialListing","modules-footer-components-Footer"]}